Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells

BACKGROUND: Several small receptor tyrosine kinase inhibitors (RTKI) have entered clinical cancer trials alone and in combination with radiotherapy or chemotherapy. The inhibitory spectrum of these compounds is often not restricted to a single target. For example Imatinib/Gleevec (primarily a bcr/ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Minglun, Ping, Gong, Plathow, Christian, Trinh, Thuy, Lipson, Kenneth E, Hauser, Kai, Krempien, Robert, Debus, Juergen, Abdollahi, Amir, Huber, Peter E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1458351/
https://www.ncbi.nlm.nih.gov/pubmed/16556328
http://dx.doi.org/10.1186/1471-2407-6-79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1458351/
https://www.ncbi.nlm.nih.gov/pubmed/16556328
http://dx.doi.org/10.1186/1471-2407-6-79

Ejemplares similares